iSpecimen Inc. ISPC
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research
Chart by TradingView
4/9
Piotroski F — financial health
-33.49
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.9M | -$10.5M | — | -$4.2M | $3.1M |
| 2024 | $9.3M | -$12.5M | — | -$8.3M | $3.3M |
| 2023 | $9.9M | -$11.1M | — | -$5.8M | $9.7M |
| 2022 | $10.4M | -$10.2M | — | -$6.0M | $20.3M |
| 2021 | $11.1M | -$9.0M | — | -$10.7M | $29.8M |
| 2020 | $8.2M | -$4.7M | — | -$288,806 | -$27.3M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -33.49 (distress)
- Working capital / assets 0.076
- Retained earnings / assets -8.64
- EBIT / assets -0.942
- Equity / liabilities 0.479
Source: SEC EDGAR filings · CIK 0001558569 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.